4D Molecular Therapeutics, Inc. (FDMT)

About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

As of November 3, 2026, 4D Molecular Therapeutics, Inc. (FDMT) stock climbed to $11.86, up 4.27% (+$0.49) versus the previous close. On the day, shares have traded between $11.46 and $12.08. That puts FDMT around the middle of its 52-week range of $6.96 to $16.93. 4D Molecular Therapeutics, Inc. operates in the biological products, (no diagnostic substances) space and carries a market capitalization of roughly $657.41 million, with about 274.5K shares changing hands.

Latest FDMT news

• 4DMT to Participate in Upcoming Investor ConferencesYahoo Finance· Nov 3, 8:00 AM ET
• Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue EstimatesYahoo Finance· Nov 3, 7:00 AM ETSTVN
• 4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Yahoo Finance· Nov 2, 9:00 AM ET
• 4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapymarketbeat.com· Oct 22, 7:02 AM ET
• Cystic Fibrosis Market Poised for Growth During the Forecast Period (2026-2036) as CFTR Modulators Transform Treatment Landscape | DelveInsightYahoo Finance· Oct 21, 10:31 AM ET
• 4DMT Announces New Employment Inducement GrantsYahoo Finance· Oct 16, 4:05 PM ET
• 4DMT to Host Investor Day on October 21, 2026Yahoo Finance· Oct 5, 8:00 AM ET
• This is the top biotech stock pick from B Riley SecuritiesYahoo Finance· Sep 29, 5:24 PM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want FDMT headlines, alerts and AI research in one place? Create a free account →

• 4D Molecular Therapeutics $FDMT will present at seven investor conferences. Starting with Guggenheim on Nov 10 at 4:30 p.m. ET and running through Dec 10. Shares closed at $11.37 on Monday, below the SMA50 and above the SMA200, RSI 41. More details in our hub. Not investment a…

  @Merlintrader· Nov 3, 11:22 AM ET

• $FDMT closed the week at $11.90 (+10.2% w/w), below the 50-day SMA ($13.72) and above the 200-day ($10.87). RSI14 44.1. 20-day range $10.62-$13.86. FDMT Stock Hub: 4D Molecular Therapeutics News, Genetic Medicines and Clinical Data https://www.merlintrader.com/4d-molecular-the…

  @Merlintrader· Nov 1, 3:19 PM ET

• $FDMT Latest company news, Oct 21, 2026: at its Investor Day, 4D Molecular Therapeutics reported 523 patients randomized in 4FRONT-1 and 531 in 4FRONT-2, its wet AMD Phase 3 studies of 4D-150. Topline results are expected in Q2 2027 and H2 2027; the DME Phase 3 4SIGHT began en…

  @Merlintrader· Oct 22, 5:30 PM ET

• $FDMT Great job, Vulture! You stopped that landslide just in time! Keep it up.

  @eeyore1· Oct 15, 3:23 PM ET

• $FDMT What is going on here? Why are we so low?

  @grizzly3· Oct 14, 3:17 PM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →